ArticleWorld journal of gastrointestinal oncology2026
Efficacy and safety of integrated Chinese and Western medicine in advanced pancreatic cancer: A double-center retrospective cohort study.
Article in World journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced pancreatic cancer (PC) is associated with a poor prognosis. The integration of Chinese and Western medicine (ICWM) has shown promising clinical efficacy. Nonetheless, the existing body of research assessing the efficacy and safety of this integrative approach is limited, hindering the provision of robust evidence-based support for clinical decision-making.
aimTo assess the short-term and long-term efficacy and safety of ICWM compared with Western medicine (WM) as a standalone treatment for advanced PC.
methodsWe enrolled 136 patients with advanced PC admitted to Henan Provincial Hospital of Traditional Chinese Medicine and Henan Provincial People's Hospital from 2019 to 2024. Patients were randomly assigned to the ICWM or WM group (
resultsThe median overall survival was 12.91 months and 10.64 months in the ICWM and WM groups, while the median progression-free survival was 5.12 months and 3.55 months, respectively. The disease control rate was significantly higher in the ICWM group than that in the the WM group, while the myelosuppression was significantly milder. The serum tumor markers carbohydrate antigen (CA) 19-9 and CA125 showed a significant downward trend before and after treatment in the ICWM group, whereas only CA19-9 showed a significant decrease in the WM group. Post-treatment, both groups showed an upward trend in natural killer cells and CD3+, CD4+, and CD4+/CD8+ lymphocytes compared with pre-treatment, with the ICWM group exhibiting a more pronounced increase. The two groups showed no significant differences in hepatic and renal function impairment.
conclusionICWM extended survival in patients with advanced PC, improved long-term efficacy, controlled local lesions, reduced serum tumor markers, enhanced immune function, and improved short-term outcomes, with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.